Happiness Biotech Group Limited
| NASDAQ: HAPP | Healthcare / Drug Manufacturers / China |
| 1.89 | -0.0253 | -1.32% | Vol 449.09K | 1Y Perf -37.62% |
| Apr 13th, 2021 16:00 DELAYED |
| BID | 1.86 | ASK | 1.91 | ||
| Open | 2.02 | Previous Close | 1.92 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 10.50 | Analyst Rating | — 0.00 | |
| Potential % | 455.56 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★★★★ 67.67 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★★★★ 73.43 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Market Cap | 48.95M | Earnings Rating | — | |
| Price Range Ratio 52W % | 12.68 | Earnings Date | - |
Today's Price Range 1.882.03 | 52W Range 1.633.68 |
Summary:
Sell
| Technical Indicators: | Sell |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -7.80% | ||
| 1 Month | -7.35% | ||
| 3 Months | -9.57% | ||
| 6 Months | 5.00% | ||
| 1 Year | -37.62% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | - | |||
ROE last 12 Months | 9.38 | |||
ROA (5Y Avg) | - | |||
ROA last 12 Months | 8.75 | |||
ROC (5Y Avg) | 35.74 | |||
ROC last 12 Months | 9.42 | |||
Return on invested Capital Q | - | |||
Return on invested Capital Y | 17.70 | |||
Assets Turnover | 0.20 | |||
Receivables Turnover | 0.80 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 5.70 | ||||
| 1.59 | ||||
| 2.19 | ||||
| 16.00 | ||||
| 74.60 | ||||
| 0.26 | ||||
| 1.59 | ||||
| 2.65 | ||||
| 83.20M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 11.20 | ||||
| 12.80 | ||||
| - | ||||
| 0.03 | ||||
| 85.10 | ||||
| Leverage Ratio | 1.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 28.70 | ||||
| 17.40 | ||||
| 18.70 | ||||
| 29.40 | ||||
| 14.56 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 21.88M | ||||
| 0.88 | ||||
| -29.92 | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 449.09K |
| Shares Outstanding | 25.90M |
| Trades Count | 1.23K |
| Dollar Volume | 1.08M |
| Avg. Volume | 1.08M |
| Avg. Weekly Volume | 175.85K |
| Avg. Monthly Volume | 235.74K |
| Avg. Quarterly Volume | 577.61K |
Happiness Biotech Group Limited (NASDAQ: HAPP) stock closed at 1.89 per share at the end of the most recent trading day (a -1.32% change compared to the prior day closing price) with a volume of 451.15K shares and market capitalization of 48.95M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 151 people. Happiness Biotech Group Limited CEO is Xuezhu Wang.
The one-year performance of Happiness Biotech Group Limited stock is -37.62%, while year-to-date (YTD) performance is 2.72%. HAPP stock has a five-year performance of %. Its 52-week range is between 1.63 and 3.68, which gives HAPP stock a 52-week price range ratio of 12.68%
Happiness Biotech Group Limited currently has a PE ratio of 5.70, a price-to-book (PB) ratio of 1.59, a price-to-sale (PS) ratio of 2.19, a price to cashflow ratio of 16.00, a PEG ratio of 2.32, a ROA of 8.75%, a ROC of 9.42% and a ROE of 9.38%. The company’s profit margin is 14.56%, its EBITDA margin is 18.70%, and its revenue ttm is $21.88 Million , which makes it $0.88 revenue per share.
Of the last four earnings reports from Happiness Biotech Group Limited, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Happiness Biotech Group Limited’s next earnings report date is -.
The consensus rating of Wall Street analysts for Happiness Biotech Group Limited is — (0), with a target price of $10.5, which is +455.56% compared to the current price. The earnings rating for Happiness Biotech Group Limited stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Happiness Biotech Group Limited has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Happiness Biotech Group Limited has a Sell technical analysis rating based on Technical Indicators (ADX : 17.07, ATR14 : 0.15, CCI20 : -168.69, Chaikin Money Flow : -0.20, MACD : -0.07, Money Flow Index : 43.04, ROC : -4.55, RSI : 39.00, STOCH (14,3) : 4.06, STOCH RSI : 0.30, UO : 30.99, Williams %R : -95.94), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Happiness Biotech Group Limited in the last 12-months were:
Happiness Biotech Group Limited
Happiness Biotech Group Ltd is a nutraceutical and dietary supplements producer focused on the research, development, manufacturing, and marketing of products made from Chinese herbal extracts. Its products include Lucidum spore powder products, Cordyceps mycelia products, Ejiao solution products, Vitamins, and dietary supplements products, American ginseng products, and others. The company generates maximum revenue from Lucidum spore powder products.
CEO: Xuezhu Wang
Telephone: +86 5997828808
Address: Number 11, Dongjiao East Road, Nanping 353200, , CN
Number of employees: 151
